Undetectable minimal residual disease should be the goal of venetoclax therapy in relapsed and refractory chronic lymphocytic leukaemia (2089)
Thomas Lew
Click the following button to download this presentation’s slides
2019 Presentations Access
Thank you for your interest in viewing the iwCLL 2019 video presentations.
Please complete the following information below to access the presentations.